Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
5-6
|
pubmed:dateCreated |
1985-6-10
|
pubmed:abstractText |
Serum thyroglobulin (Tg) was measured in 429 patients with well-differentiated thyroid carcinoma, during thyroid hormone suppression therapy. 324 patients out of 429 were considered free of disease; 44 had only remnants in the thyroid bed; 61 had metastases, of them 40 were detected by TBS and 21 were nonfunctioning and were detected by other diagnostic procedures. Tg was measured by a RIA method in 257 patients and by an IRMA method in 277 patients. The correlation between the two methods was very good (r = 0.914) for values higher than 25 ng/ml with the RIA method. The cut-off limit to distinguish pathological from nonpathological values was considered the mean value found in the patients free of disease plus 2SD. The cut-off limit for the RIA method was 24.2 ng/ml and 3.0 ng/ml for the IRMA method. Of patients with high Tg levels 92% had metastases, either nodal or distant; only 8% had remnants in the thyroid bed. Tg levels were high in 80% of the patients with metastases, all but two of the patients with metastases and low Tg levels had nodal metastases. Moreover, Tg levels were high in 76% of the patients with metastases unable to take up radioiodine. In conclusion: patients with low levels of serum Tg during suppression therapy have a high probability of being free of disease, even though the presence of tumors cannot be excluded. On the other hand a value greater than the cut-off limit suggests the presence of metastases despite a negative scan.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Iodine Radioisotopes,
http://linkedlifedata.com/resource/pubmed/chemical/Thyroglobulin,
http://linkedlifedata.com/resource/pubmed/chemical/Thyrotropin,
http://linkedlifedata.com/resource/pubmed/chemical/Thyroxine,
http://linkedlifedata.com/resource/pubmed/chemical/Triiodothyronine
|
pubmed:status |
MEDLINE
|
pubmed:issn |
0340-6997
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
252-4
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:3987701-Adenocarcinoma,
pubmed-meshheading:3987701-Adolescent,
pubmed-meshheading:3987701-Adult,
pubmed-meshheading:3987701-Aged,
pubmed-meshheading:3987701-Carcinoma, Papillary,
pubmed-meshheading:3987701-Combined Modality Therapy,
pubmed-meshheading:3987701-Female,
pubmed-meshheading:3987701-Humans,
pubmed-meshheading:3987701-Iodine Radioisotopes,
pubmed-meshheading:3987701-Male,
pubmed-meshheading:3987701-Middle Aged,
pubmed-meshheading:3987701-Neoplasm Metastasis,
pubmed-meshheading:3987701-Thyroglobulin,
pubmed-meshheading:3987701-Thyroid Neoplasms,
pubmed-meshheading:3987701-Thyroidectomy,
pubmed-meshheading:3987701-Thyrotropin,
pubmed-meshheading:3987701-Thyroxine,
pubmed-meshheading:3987701-Triiodothyronine
|
pubmed:year |
1985
|
pubmed:articleTitle |
Serum thyroglobulin levels in patients with well-differentiated thyroid cancer during suppression therapy: study on 429 patients.
|
pubmed:publicationType |
Journal Article
|